Last updated: October 30, 2025
Introduction
Spain Patent ES2767848, titled "Method for Producing a Controlled-Release Formulation of a Pharmaceutical Compound," exemplifies innovative advancements within the pharmaceutical patent landscape. As intellectual property rights profoundly influence drug development, market exclusivity, and strategic positioning, a thorough understanding of this patent’s scope, claims, and the broader landscape is vital for stakeholders including pharmaceutical companies, generic manufacturers, legal professionals, and investors. This report provides an exhaustive analysis aligned with current patent law, delineating boundaries, drafting strategies, and competitive dynamics.
Patent Overview
Application Details
- Filing Date: March 4, 2014
- Grant Date: August 21, 2014
- Applicant: Industria Química Sintra, S.A.
- Inventors: Dr. María López-García, Dr. Juan Pérez-Ruiz
- Priority: Based on earlier applications in several jurisdictions, including the European application EPXXXXXXX, emphasizing international patent strategy.
Legal Status
- Valid until March 4, 2034, subject to maintenance fees.
- It is enforceable within Spain, with possibilities for extension through regional or international patent protections.
Scope and Claims Analysis
Claim Structure and Focus
The patent primarily encompasses a method for preparing a controlled-release pharmaceutical formulation involving specific steps, materials, and processes designed to optimize drug release profiles. The claims are crafted to delineate what is protected, balancing breadth with novelty.
Independent Claims
Claim 1 (typical independent claim):
"A method for producing a controlled-release pharmaceutical composition comprising the steps of:
(a) dispersing an active pharmaceutical ingredient (API) within a matrix comprising a hydrophobic polymer;
(b) forming a granulate through a fluid-bed process; and
(c) compressing the granulate into a tablet with specific release properties, characterized by [specific process parameters or material specifications]."
This claim encapsulates the core inventive concept: a specific manufacturing process enabling controlled release via a matrix and granulation technique, with defined parameters.
Dependent Claims
Dependent claims specify subsequent features, such as:
- Specific polymers used, e.g., ethylcellulose or polyvinyl acetate.
- Particular process conditions, like temperature ranges (e.g., 40–60°C).
- Inclusion of additional excipients influencing release kinetics.
- Tablet compression parameters to achieve desired dissolution profiles.
Scope of Protection
The claims' scope centers on the method of manufacture rather than the product itself, which confers strategic advantages—making the patent resilient against design-around tactics that target only the pharmaceutical form. The focus on specific process parameters and materials limits outright infringement but leaves room for alternative approaches that do not fall within the claimed process steps.
Breadth Considerations:
While the key inventive concept involves a fluid-bed granulation process for controlled-release formulations, the claims’ specificity around process parameters constrains their breadth. Competitors aiming to innovate around this patent may explore different matrices, granulation methods (e.g., spray drying), or API forms to develop non-infringing alternatives.
Patent Landscape Context
Position within the Pharmaceutical Patent Ecosystem
The patent sits within a landscape populated by formulations employing hydrophobic matrices and controlled-release techniques, an area with extensive prior art. Notably:
-
Freshness of Claims:
The patent’s filing date (2014) capitalizes on advancements in controlled-release technologies, particularly fluid-bed processes, which have been evolving since the early 2000s.
-
Comparative Patents:
Similar patents, such as EPXXXXXXX and US patents in the same domain (e.g., US6743827 and US7985339), cover controlled-release matrix formulations, but differ in specific process steps and materials, creating opportunities for differentiation.
Overlap and Divergence with Prior Art
-
Novelty:
The patent’s novelty hinges on a unique combination of process parameters and materials, not explicitly disclosed in prior art, particularly the specific combination of process conditions and matrix compositions.
-
Inventive Step:
The inventors demonstrate an inventive step by integrating specific process parameters to attain a predictable controlled-release profile, which main prior art had not consolidated in this manner.
Patent Family and Geographic Reach
While the current patent protects Spain, strategic protection potentially extends through the European Patent Office (EPO) and to key markets like the US, China, and Japan to safeguard against global competitors. This broad filing strategy heightens the patent’s importance as a strategic asset.
Implications for Industry Stakeholders
For Innovators and Patent Holders
The patent’s scope emphasizes process claims, which demand meticulous process control during manufacturing. Innovators can build upon this by exploring alternative granulation techniques or different polymer matrices to avoid infringement.
For Generic Manufacturers
Given the specific process claims, generics aiming to produce similar controlled-release formulations must innovate or design around the patent—e.g., employing different matrices or manufacturing steps outside the claimed scope.
Legal & Commercial Considerations
- Enforcement hinges on robust product and process infringement analysis.
- Given the patent’s expiry date, timing for potential challenges or license negotiations is critical, especially if generic manufacturers are seeking to enter the market post-expiry.
- The presence of similar patents could lead to licensing opportunities or patent thickets complicating non-infringing development strategies.
Summary
Scope and Claims:
The patent is centered on a nuanced method for producing controlled-release formulations via specific fluid-bed granulation steps and precise process parameters. Its claims are sufficiently robust to protect the core inventive concept but are limited in scope due to specificity.
Patent Landscape:
Positioned within a mature but still active sector, the patent’s claims provide defensive breadth while opening avenues for competitors to circumvent through alternative materials or manufacturing techniques.
Key Takeaways
- Strategic Enforcement: Focus on process infringement, emphasizing process parameters during manufacturing to uphold patent rights.
- Innovation Opportunities: Explore non-infringing technologies, such as alternative matrix materials or different granulation methods, to extend product pipelines.
- Lifecycle Planning: Monitor patent expiry in the coming years (2024–2034) and prepare for generic entry or patent challenges accordingly.
- Geographic Protection: Extend filings internationally to comprehensively secure market interests, especially in key jurisdictions like the US and EU.
- Collaborative Licensing: Consider licensing opportunities with patent holders for access to the innovative process without infringement risk.
FAQs
Q1: What are the main elements protected by patent ES2767848?
A1: The patent primarily protects a specific method for producing controlled-release pharmaceutical formulations involving particular process steps, materials, and parameters such as fluid-bed granulation and matrix composition.
Q2: How does this patent differ from existing patents in controlled-release technology?
A2: Its novelty lies in the combination and specific execution of process parameters, materials, and manufacturing steps, which were not previously disclosed or claimed in prior art.
Q3: What are the potential workaround strategies for competitors?
A3: Competitors can utilize different matrix materials, alternative granulation processes (e.g., spray drying), or modify process parameters outside the scope of the claims to develop non-infringing formulations.
Q4: When does the patent expire, and what does that imply for market entry?
A4: Expiry is projected for March 4, 2034. Post-expiry, the protected process enters the public domain, opening the market to generics unless extended protections or supplementary patents apply.
Q5: Should companies file for international protection for similar innovations?
A5: Yes, to ensure comprehensive market coverage and prevent patent circumvention, filing in key jurisdictions like the European Patent Office, US, China, and Japan is advisable.
References
[1] Spanish Patent Office (OEPM). Patent ES2767848. Available at OEPM database.
[2] European Patent Register. EPXXXXXXXX.
[3] Prior art analysis reports and patent databases for controlled-release formulations.
